STOCK TITAN

Prime Medicine (PRME) director and 10% owner receives 75,000-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Prime Medicine director and 10% owner Robert Nelsen received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, all 75,000 underlying shares vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, assuming he continues to provide service to the company through that vesting date. This is a compensation-related award, not an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider NELSEN ROBERT
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 75,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 75,000 options Stock Option (right to buy) on Common Stock
Exercise price $3.06 per share Conversion or exercise price of stock options
Shares underlying options 75,000 shares Underlying Common Stock associated with the options
Total derivative holdings after grant 75,000 options Total shares following transaction for this option award
Vesting date trigger June 5, 2027 Full vesting or earlier at next annual stockholder meeting
Option expiration June 5, 2036 Expiration date of the stock option grant
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 3.0600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"shares subject to this option shall vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NELSEN ROBERT

(Last)(First)(Middle)
8755 WEST HIGGINS ROAD, SUITE 1025

(Street)
CHICAGO ILLINOIS 60631

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$3.0606/05/2026A75,000 (1)06/05/2036Common Stock75,000$075,000D
Explanation of Responses:
1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s/ Ryan Brown, attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Robert Nelsen report in this Form 4 for Prime Medicine (PRME)?

Robert Nelsen reported receiving a grant of stock options for 75,000 shares of Prime Medicine Common Stock. The options are compensation-related, not an open-market transaction, and give him the right to buy shares at a fixed exercise price in the future.

How many Prime Medicine (PRME) shares are covered by Nelsen’s new stock options?

The new stock option grant covers 75,000 shares of Prime Medicine Common Stock. These options represent the right, but not the obligation, to purchase that number of shares if and when the options vest and are exercised later.

What is the exercise price of Robert Nelsen’s Prime Medicine (PRME) stock options?

The options have an exercise price of $3.06 per share. This means Nelsen can buy Prime Medicine Common Stock at $3.06 per share once the options vest and before they expire, regardless of the market price at that time.

When do Robert Nelsen’s Prime Medicine (PRME) stock options vest?

The options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting. Vesting is contingent on Nelsen’s continuous service to the company through the applicable vesting date, as specified in the grant terms.

When do Robert Nelsen’s Prime Medicine (PRME) stock options expire?

The stock options expire on June 5, 2036. After this expiration date, any unexercised options become worthless, so Nelsen must exercise vested options before that date if he wants to purchase the underlying shares.

Is this Prime Medicine (PRME) Form 4 a stock purchase or a sale by Robert Nelsen?

The Form 4 reflects a grant of stock options to Robert Nelsen, not a purchase or sale in the open market. The transaction is coded as an award, giving him the right to buy shares later rather than immediately changing his shareholdings.